XenoPort announces positive results of a Phase 1 clinical trial of XP21279
SANTA CLARA, Calif. XenoPort, Inc. today announced positive results from a Phase 1 clinical trial of XP21279, a Transported Prodrug of levodopa, or L-Dopa.
Varian Medical Systems today is celebrating its tenth anniversary and a decade of growth and innovation in life-saving technology utilizing X-ray energy for cancer treatment, imaging, and security and inspection.